Growth Metrics

Integra Lifesciences Holdings (IART) Total Debt (2016 - 2026)

Integra Lifesciences Holdings' Total Debt history spans 17 years, with the latest figure at $1.7 billion for Q4 2025.

  • On a quarterly basis, Total Debt rose 54.17% to $1.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 billion, a 54.17% increase, with the full-year FY2025 number at $1.7 billion, up 54.17% from a year prior.
  • Total Debt hit $1.7 billion in Q4 2025 for Integra Lifesciences Holdings, up from $1.7 billion in the prior quarter.
  • Over the last five years, Total Debt for IART hit a ceiling of $1.7 billion in Q4 2025 and a floor of $769.1 million in Q1 2023.
  • Historically, Total Debt has averaged $1.1 billion across 5 years, with a median of $870.5 million in 2022.
  • Biggest five-year swings in Total Debt: decreased 14.76% in 2021 and later surged 54.77% in 2024.
  • Tracing IART's Total Debt over 5 years: stood at $869.3 million in 2021, then fell by 11.27% to $771.3 million in 2022, then grew by 7.04% to $825.6 million in 2023, then soared by 35.89% to $1.1 billion in 2024, then skyrocketed by 54.17% to $1.7 billion in 2025.
  • Business Quant data shows Total Debt for IART at $1.7 billion in Q4 2025, $1.7 billion in Q3 2025, and $1.7 billion in Q2 2025.